Published on 22 Dec 2022 on Seeking Alpha
Since our last publication on Abiomed, Inc. (NASDAQ:ABMD) where we had a buy thesis fully intact,...
Abiomed, Inc. ABMD is well-poised for growth in the coming quarters, backed by strength in its...
Abiomed, Inc. ABMD is well-poised for growth in the coming quarters, backed by strength in its Im...
Since our last publication on Abiomed, Inc. (NASDAQ:ABMD) where we had a buy thesis fully intact,...
Shares of Abiomed Inc. inched 0.06% higher to $381.02 Wednesday, on what proved to be an all-arou...
Shares of Abiomed Inc. inched 0.08% higher to $381.30 Monday, on what proved to be an all-around ...
Along with an interest rate hike of 50 bps at the FOMC meeting last week, the Fed officials signa...
Given an uncertain market backdrop, investors should buy fundamentally sound and dividend-paying...
Shares of Abiomed Inc. slid 0.19% to $380.01 Monday, on what proved to be an all-around positive ...
The U.S. biotech company’s deal for the drugmaker, which develops medicines to treat autoimmune a...
Given the uncertain market backdrop, it could be wise to invest in fundamentally sound and resili...
Copyright Statfolio @ 2024